© 2002 by Annals of the Rheumatic Diseases
PREFACE
Advances in targeted therapies IV
1 University of Leiden
2 University of Erlangen
3 University of Vienna
Keywords: tumour necrosis factor 
| The first 150 words of the full text of this article appear below. |
The papers brought together in this supplement of the Annals of the Rheumatic Diseases constitute summaries of presentations at the Fourth International Symposium on Advances in Targeted Therapies which was held in April/May 2002. As such, these presentations represent the state of the art on the biology of mechanisms of action and pathophysiology of tumour necrosis factor (TNF) and interleukin (IL1) as well as other important mediators of inflammation. Current knowledge on the means and consequences of blocking TNF, IL1, or other molecules is presented as well.
We are grateful to Drs Crofford, Feldmann, Furst, Klareskog, Lipsky, Maini, Moreland, and Weinblatt, the members of the advisory board of the symposium, for their invaluable help towards the success of the conference, the fourth of a series of similar events planned for the future. We particularly wish to thank all speakers for their excellent presentations, most of which are summarised here in
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
